Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros
大量零值纵向患者报告结局与生存时间的多层贝叶斯模型
Regulatory approval of new therapies often depends on demonstrating prolonged survival. Particularly when these survival benefits are modest, consideration of therapeutic benefits to patient-reported outcomes (PROs) may add value to the traditional biomedical clinical trial endpoints. We extend a popular class of joint models for longitudinal and survival data to accommodate the excessive zeros common in PROs, building hierarchical Bayesian models that combine information…